Maheshwari Shubhrat, Singh Aditya
Faculty of Pharmaceutical Sciences, Rama University, Mandhana, Bithoor Road, Kanpur, Uttar Pradesh, 209217, India.
Department of Pharmacy, Faculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, 226026, India.
Recent Pat Nanotechnol. 2025;19(3):356-363. doi: 10.2174/1872210517666230831154408.
Cells and nervous system connections that are crucial for movement, coordination, strength, sensation, and thought are gradually damaged in neurodegenerative illnesses. Amyloid beta (Aβ)- accumulating macromolecules in the brain are the primary cause of the disease's chronic symptoms, according to analysis carried out during the last 20 years. Plaques and clumps of amyloid- build up in the brain, obstructing neuronal signals and destroying neural connections. Tau, a protein that results in the formation of "neurofibrillary tangles" in the brain, another hallmark of neuronal death, has been the focus of a lot of research. Dendrimers Delivery (DDs) is one of the most promising advancements in nanotechnology for biomedical applications, particularly drug delivery. Some of the main categories of dendrimers employed in the successful management of neurodegenerative illnesses are polyamidoamine dendrimers (PAMAM) dendrimers, polypropylenimine dendrimers (PPI), Poly-l-lysine dendrimers (PLL), and carbosilane dendrimers. The tight blood-brain barrier (BBB), which limits the entry of medications or therapeutic agents, makes it difficult to treat central nervous system disorders. Dendrimers have attracted the attention of scientists more than other non-invasive methods of drug delivery across the BBB and improve the uptake of medicines in the brain's target tissues. The major benefits of dendrimers include their adaptability, biocompatibility, ability to load pharmaceuticals into the core and surface, and nanosize. The patents provide "composition of matter" protection for Starpharma's dendrimer technologies for drug delivery out to 2029 in the United States, which is the world's largest pharmaceutical market for several important drug classes. This review has updated the status of the patent and clinical trials literature pertaining to dendrimer use in AD.
在神经退行性疾病中，对运动、协调、力量、感觉和思维至关重要的细胞和神经系统连接会逐渐受损。根据过去20年的分析，大脑中积累淀粉样β蛋白（Aβ）的大分子是该疾病慢性症状的主要原因。淀粉样斑块和团块在大脑中积聚，阻碍神经元信号并破坏神经连接。tau蛋白是导致大脑中形成“神经原纤维缠结”的一种蛋白质，这是神经元死亡的另一个标志，一直是许多研究的重点。树枝状大分子递送（DDs）是纳米技术在生物医学应用中最有前景的进展之一，尤其是药物递送。成功用于治疗神经退行性疾病的一些主要树枝状大分子类别包括聚酰胺胺树枝状大分子（PAMAM）、聚亚丙基亚胺树枝状大分子（PPI）、聚-L-赖氨酸树枝状大分子（PLL）和碳硅烷树枝状大分子。紧密的血脑屏障（BBB）限制了药物或治疗剂的进入，使得治疗中枢神经系统疾病变得困难。与其他非侵入性的血脑屏障药物递送方法相比，树枝状大分子更吸引科学家的关注，并能提高药物在大脑靶组织中的摄取。树枝状大分子的主要优点包括其适应性、生物相容性、将药物加载到核心和表面的能力以及纳米尺寸。这些专利为Starpharma公司用于药物递送的树枝状大分子技术在美国提供了“物质组成”保护，直至2029年，美国是几种重要药物类别的全球最大制药市场。本综述更新了与树枝状大分子在阿尔茨海默病中的应用相关的专利和临床试验文献的现状。
